Everolimus
Title: Everolimus
CAS Registry Number: 159351-69-6
CAS Name: 42-O-(2-Hydroxyethyl)rapamycin
Additional Names: 40-O-(2-hydroxyethyl)rapamycin
Manufacturers' Codes: RAD-001; SDZ RAD
Trademarks: Certican (Novartis)
Molecular Formula: C53H83NO14
Molecular Weight: 958.22
Percent Composition: C 66.43%, H 8.73%, N 1.46%, O 23.38%
Literature References: Macrolide immunosuppressant; derivative of rapamycin, q.v. Inhibits cytokine-mediated lymphocyte proliferation. Prepn: S. Cottens, R. Sedrani, WO 9409010; eidem, US 5665772 (1994, 1997 both to Sandoz). Pharmacology: W. Schuler et al., Transplantation 64, 36 (1997). Whole blood determn by LC/MS: N. Brignol et al., Rapid Commun. Mass Spectrom. 15, 898 (2001); by HPLC: S. Baldelli et al., J. Chromatogr. B 816, 99 (2005). Clinical pharmacokinetics in combination with cyclosporine: J. M. Kovarik et al., Clin. Pharmacol. Ther. 69, 48 (2001). Clinical study in prevention of cardiac-allograft vasculopathy: H. J. Eisen et al., N. Engl. J. Med. 349, 847 (2003). Review: F. J. Dumont et al., Curr. Opin. Invest. Drugs 2, 1220-1234 (2001); B. Nashan, Ther. Drug Monit. 24, 53-58 (2002).
Therap-Cat: Immunosuppressant.
Keywords: Immunosuppressant.

Others monographs:
OpromazineBimatoprostCinepazideAmmonium Sulfamate
HydroxytetracaineOil of FleabanePiperazineAcrylonitrile
IchthyopterinPentachloroethaneIndoraminIsobutyl Carbamate
Niobium PentoxideCaryophylleneNicoclonateProtiofate
©2016 DrugLead US FDA&EMEA